News tagged with tumor response
CT imaging taken post avastin may predict survival in patients with metastatic colorectal cancer
Dec 01, 2009 |
not rated yet |
0
Using routine computed tomography (CT) imaging to analyze form and structural changes to colorectal liver metastasis after bevacizumab and chemotherapy may predict overall survival, according to research from The University ...
Glitches in DNA repair genes predict prognosis in pancreatic cancer
Jan 14, 2009 |
5 / 5 (1) |
0
Variations in mismatch repair genes can help predict treatment response and prognosis in patients with pancreatic cancer, according to research from The University of Texas M. D. Anderson Cancer Center presented today in ...
Angiogenesis inhibitor improves brain tumor survival by reducing edema
Mar 30, 2009 |
not rated yet |
0
The beneficial effects of anti-angiogenesis drugs in the treatment of the deadly brain tumors called glioblastomas appear to result primarily from reduction of edema - the swelling of brain tissue - and not from any direct ...
Search results for tumor response
'Self-seeding' of cancer cells may play a critical role in tumor progression
Dec 24, 2009 |
5 / 5 (4) |
0
Cancer progression is commonly thought of as a process involving the growth of a primary tumor followed by metastasis, in which cancer cells leave the primary tumor and spread to distant organs. A new study by researchers ...
Figitumumab has anti-tumor activity in Ewing's sarcoma
Dec 23, 2009 |
not rated yet |
0
A preliminary study of the anticancer drug figitumumab has found that it has antitumour activity in Ewing's sarcoma—a cancer which affects mainly teenage boys. The results have led to the drug's progression to a Phase 2 trial ...
Research yields new agent for some drug-resistant non-small cell lung cancers
Dec 23, 2009 |
5 / 5 (1) |
0
The ability to make, test, and map the atomic structure of new anti-cancer agents has enabled a team of Dana-Farber Cancer Institute scientists to discover a compound capable of halting a common type of drug-resistant ...
Enzyme necessary for development of healthy immune system
Dec 22, 2009 |
not rated yet |
0
Mice without the deoxycytidine kinase (dCK) enzyme have defects in their adaptive immune system, producing very low levels of both T and B lymphocytes, the major players involved in immune response, according to a study by ...
Tracking new cancer-killing particles with MRI
Nanotechnology / Nanomaterials
Dec 14, 2009 |
5 / 5 (4) |
0
Researchers at Rice University and Baylor College of Medicine (BCM) have created a single nanoparticle that can be tracked in real time with MRI as it homes in on cancer cells, tags them with a fluorescent ...
Clinical trial advances new approach to re-sensitizing breast cancer
Dec 13, 2009 |
not rated yet |
0
A new drug cocktail might be the right mix to fight breast cancer after it becomes resistant to standard therapy. Details of a new study supporting this approach suggest it's possible to re-sensitize tumors thus allowing ...
Obesity linked with poorer breast cancer outcomes
Dec 10, 2009 |
not rated yet |
0
Breast cancer patients with a high body mass index (BMI) have a poorer cancer prognosis later in life. Specifically, their treatment effect does not last as long and their risk of death increases.
Sonic Hedgehog variations linked to recurrence, survival and response to therapy of bladder cancer
Dec 09, 2009 |
not rated yet |
0
Genetic variations in the Sonic Hedgehog pathway increase the likelihood of recurrence, reduce survival time and limit response to therapy for people with non-muscle invasive bladder cancer, scientists from The University ...
Small addition to cancer drug may make big difference
Dec 08, 2009 |
3 / 5 (2) |
0
University of Florida researchers have found a way to use just a fraction of the normal dosage of a highly toxic, debilitating chemotherapy drug to achieve even better results against colon cancer cells.
Drug shows positive responses, low side-effects in multiple myeloma
Dec 07, 2009 |
not rated yet |
0
NEW ORLEANS ― The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers ...
List of search results for tumor response
